Chinese Traditional and Herbal Drugs
|
2025, 56(20): 7395-7406
Dihydroartemisinin ameliorates hepatic glucose metabolism disorder and inflammatory response in mice with type 2 diabetes mellitus through FOXO1/HK2/G6PC and MyD88/NF-κB pathways
Full
ZHANG Yu, YANG Yuanmin, LI Yu, CHEN Lina, LIU Tuo, WANG Kun, LI Yujie
Affiliations
doi: 10.7501/j.issn.0253-2670.2025.20.012
Outline
Objective To investigate the effect and mechanism of dihydroartemisinin (DHA) on hepatic glucose metabolism disorder and inflammatory reaction in mice with type 2 diabetes (T2DM). Methods A T2DM mouse model was established by feeding a high sugar and high-fat diet combined with ip streptozotocin (40 mg/kg). Control group, model group, metformin (200 mg/kg) group, DHA low-, medium-, and high-dose (30, 60, 120 mg/kg) groups were set up, with six mice in each group. After four weeks of drug intervention, body weight, fasting blood glucose (FBG), homeostatic model assessment for insulin resistance (HOMA-IR), blood lipids, and liver function indicators of mice were measured; ELISA was used to detect the levels of interleukin-1β (IL-1β), IL-6 and tumor necrosis factor-α (TNF-α) in liver tissue; Hematoxylin-eosin (HE), PAS and Oil Red O staining were used to observe pathological changes in pancreatic islets and liver tissues; Immunohistochemistry was used to detect F4/80 positive expression in liver tissue; Western blotting was used to detect the expressions of glucose metabolism and inflammatory pathway related proteins in liver tissue. An insulin resistance human hepatocellular carcinoma (IR-HepG2) model induced by high concentration insulin was established, after intervention with DHA and hexokinase (HK) inhibitor 3-bromopyruvic acid (3-BrPA), cell survival rate and glucose consumption were measured. Results Compared with model group, DHA significantly reduced FBG (P < 0.05, 0.01), improved glucose tolerance injury (P < 0.05, 0.01), reduced HOMA-IR (P < 0.01, 0.001), increased high-density lipoprotein cholesterol (HDL-C) level (P < 0.05, 0.01), decreased triglyceride (TG) level (P < 0.001), decreased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities (P < 0.05), and reduced inflammatory factor levels in liver of mice (P < 0.05, 0.01, 0.001). Pathological staining results showed that DHA could increase the pancreatic islet area in mice (P < 0.001), improve beta cell damage and liver cell atrophy, reduce lipid accumulation in liver, and increase liver glycogen content. Immunohistochemistry results showed that DHA could reduce the positive expression of F4/80 in liver. Western blotting results showed that DHA significantly down-regulated the expressions of forkhead box O1 (FOXO1), glucose-6-phosphate (G6PC), myeloid differentiation factor 88 (MyD88), nuclear factor-κB (NF-κB) and F4/80 protein in liver (P < 0.05, 0.01, 0.001), and up-regulated the expression of HK2 protein (P < 0.01). The cell experiment results showed that treating HepG2 cells with 1 μmol/L insulin for 36 h could successfully construct IR-HepG2 model; After DHA intervention, glucose consumption was significantly increased (P < 0.05, 0.01); After simultaneous intervention with DHA and 3-BrPA, 3-BrPA partially inhibited the up-regulation effect of DHA on glucose consumption. Conclusion DHA reduces FBG, improves insulin resistance and glucose tolerance, protects pancreatic islets and liver cells by regulating FOXO1/HK2/G6PC and MyD88/NF-κB pathways, thereby improving hepatic glucose metabolism disorders and inflammatory responses in T2DM mice.
dihydroartemisinin
/
type 2 diabetes mellitus
/
HepG2 cells
/
FOXO1/HK2/G6PC pathway
/
MyD88/NF-κB pathway
张雨, 杨源民, 李玉, 陈利娜, 刘拓, 汪坤, 李玉洁.
双氢青蒿素通过FOXO1/HK2/G6PC和MyD88/NF-κB通路改善2型糖尿病小鼠肝脏糖代谢紊乱和炎症反应.
中草药,
2025
, 56
(20)
: 7395
-7406
.
DOI: 10.7501/j.issn.0253-2670.2025.20.012
ZHANG Yu, YANG Yuanmin, LI Yu, CHEN Lina, LIU Tuo, WANG Kun, LI Yujie.
Dihydroartemisinin ameliorates hepatic glucose metabolism disorder and inflammatory response in mice with type 2 diabetes mellitus through FOXO1/HK2/G6PC and MyD88/NF-κB pathways[J].
Chinese Traditional and Herbal Drugs,
2025
, 56
(20)
: 7395
-7406
.
DOI: 10.7501/j.issn.0253-2670.2025.20.012
Year 2025 volume 56 Issue 20
48
12
Cite this Article
BibTeX
Article Info
doi: 10.7501/j.issn.0253-2670.2025.20.012
- Receive Date:2025-07-25
- Online Date:2026-11-13